Systemic Mastocytosis - Pipeline Review, H1 2018

  • ID: 4531948
  • Report
  • 156 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • AbbVie Inc
  • Arog Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Co
  • Patara Pharma Inc
  • MORE
Systemic Mastocytosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2018, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights:

This latest pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 1 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • AbbVie Inc
  • Arog Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Co
  • Patara Pharma Inc
  • MORE
Introduction

Report Coverage

Systemic Mastocytosis - Overview

Systemic Mastocytosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Systemic Mastocytosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Mastocytosis - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc

Arog Pharmaceuticals Inc

Blueprint Medicines Corp

Bristol-Myers Squibb Co

Deciphera Pharmaceuticals LLC

Patara Pharma Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Systemic Mastocytosis - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avapritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenolanib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ripretinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic Mastocytosis - Dormant Projects

Systemic Mastocytosis - Discontinued Products

Systemic Mastocytosis - Product Development Milestones

Featured News & Press Releases

Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

Dec 10, 2017: Blueprint Medicines: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data

Nov 01, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition

Nov 01, 2017: Seattle Genetics to Present Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program at ASH 2017

Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285

Mar 27, 2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences

Dec 04, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting

Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016

Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis

Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis

Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting

Dec 09, 2012: Seattle Genetics Highlights Adcetris Data In CD30-Positive Non-Hodgkin Lymphomas And Other Malignancies From Multiple Presentations At ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Systemic Mastocytosis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Systemic Mastocytosis - Pipeline by AB Science SA, H1 2018

Systemic Mastocytosis - Pipeline by AbbVie Inc, H1 2018

Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H1 2018

Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H1 2018

Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Co, H1 2018

Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H1 2018

Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H1 2018

Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H1 2018

Systemic Mastocytosis - Dormant Projects, H1 2018

Systemic Mastocytosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Systemic Mastocytosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • Arog Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Co
  • Deciphera Pharmaceuticals LLC
  • Patara Pharma Inc
  • Seattle Genetics Inc
  • Stemline Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll